ArticleJournal of immunology (Baltimore, Md. : 1950)2018
Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against
Open access · bronzeAbstract read
In one paragraph
Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- C1q as a target molecule to treat human disease: What do mouse studies teach us?Frontiers in immunology · 2022Pooled it
- Pre-clinical efficacy of a C4BP hexameric IgG Fc fusion protein against Neisseria gonorrhoeae.PloS one · 2026Article
- Complement therapeutic factor H-IgG proteins as pre-exposure prophylaxes against Lyme borreliae infections.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- Complement therapeutic Factor H-IgG proteins as pre-exposure prophylaxes against Lyme borreliae infections.bioRxiv : the preprint server for biology · 2024Article
- PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Mechanisms by which Factor H protectsFrontiers in immunology · 2024Article
- Vertebrate and Invertebrate Animal and New In Vitro Models for StudyingPathogens (Basel, Switzerland) · 2023Review
- Deceiving and escaping complement - the evasive journey of the malaria parasite.Trends in parasitology · 2022Review
- An optimized Factor H-Fc fusion protein against multidrug-resistantFrontiers in immunology · 2022Article
- Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection.The Journal of infectious diseases · 2021Article
- Review
- Serum Complement Activation by C4BP-IgM Fusion Protein Can Restore Susceptibility to Antibiotics inFrontiers in immunology · 2021Article
- TheVaccines · 2020Article
- Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-ResistantFrontiers in immunology · 2020Article
- Antibacterial Fusion Proteins EnhanceFrontiers in immunology · 2020Article
- C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections.JCI insight · 2019Article
- Role of Gonococcal Neisserial Surface Protein A (NspA) in Serum Resistance and Comparison of Its Factor H Binding Properties with Those of Its Meningococcal Counterpart.Infection and immunity · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Jutamas ShaughnessyDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.ORCID 0000-0003-0832-9954
Lisa A LewisDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.ORCID 0000-0001-9469-9083
Bo ZhengDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.ORCID 0000-0002-2237-2898
Caleb CarrDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.ORCID 0000-0001-6912-6937
Isaac BassDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.
Sunita GulatiDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.
Rosane B DeOliveiraDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.
Severin GoseSan Francisco Department of Public Health, San Francisco, CA 94102; and.
George W ReedDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.
Marina BottoFaculty of Medicine, Imperial College London, London SW7 2AZ, United Kingdom.
Peter A RiceDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.
Sanjay RamDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605; sanjay.ram@umassmed.edu.
University of Massachusetts Chan Medical School · USImperial College London · GBSan Francisco Department of Public Health · US
Funding
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoeaR01AI132296 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2017 to 2021
$5.5MImmune defenses against Neisseria gonorrhoeaeR01AI114790 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2015 to 2019
$3.1MVaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia coU01AI118161 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY · 2014 to 2017
$2.0MLipooligosaccharide mimitope vaccines against Neisseria gonorrhoeaeR01AI114710 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GULATI, SUNITA, RICE, PETER A. · 2015 to 2018
$1.8MGonorrhea and HIV prevention with intravaginal ring drug deliveryR61AI136007 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MOSS, JOHN A, RAM, SANJAY · 2018 to 2019
$1.0MNovel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeaeR21AI111728 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, SHAUGHNESSY, JUTAMAS · 2014 to 2015
$460kA novel anti-gonorrhea immunotherapeuticR41AI129106 · NIAID · PLANET BIOTECHNOLOGY, INC. · PI RAM, SANJAY, WYCOFF, KEITH · 2017 to 2017
$242kNIAID NIH HHS R01 AI114710NIAID NIH HHS R01 AI114790NIAID NIH HHS R01 AI132296NIAID NIH HHS R21 AI111728NIAID NIH HHS R41 AI129106NIAID NIH HHS R61 AI136007NIAID NIH HHS U01 AI118161
Abstract
Novel therapeutics against multidrug-resistant
Indexed as
GonorrheaImmunoglobulin Fc FragmentsAnimalsComplement Factor HHumansImmunoglobulin GImmunotherapyMiceNeisseria gonorrhoeaeRecombinant Fusion ProteinsCFH protein, humanComplement Factor HImmunoglobulin Fc FragmentsImmunoglobulin GRecombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.